

CS/NSE&BSE/BM/2020-21
June 18, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. June 18, 2020, has taken on record and approved the Audited Standalone and Consolidated Financial Results of the Company under Ind AS for the quarter and for the year ended 31st March, 2020 and approved the following matters.

- 1) Audited Standalone and Consolidated Financial Results under Ind AS for the quarter and for the financial year ended 31st March, 2020
- 2) Auditor's Reports of the Statutory Auditors on the Financial Results
- 3) A copy of the News Release of our company
- 4) Declaration in respect of Audit Reports with unmodified opinion
- 5) Disclosure of details of Key Managerial Personnel ("KMP") for determining materiality under Regulation 30(5) of SEBI (LODR) Regulations, 2015
- 6) Disclosure as per Regulation 33 of SEBI LODR Regulations on impact analysis of COVID-19 pandemic on company's operations.
- 7) Approved the appointment of Independent Director Mr. D.G. Prasad on the Board of WOS (i.e., Suven Pharma Inc.,) and

Suven Pharmaceuticals Limited

8) AGM Date - We are working on the date of 2nd AGM of the Company for the financial year 2019-20 which will be intimated in due course.

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 14:30 P.M.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**

A handwritten signature in blue ink, appearing to read "K Hanumantha Rao".

K Hanumantha Rao
Company Secretary

Encl: as above

Suven Pharmaceuticals Limited



SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31st Mar ' 2020.

(Rs. In Lakhs)

PART - I		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2020	31/12/2019	31/03/2019	31/03/2020	31/03/2019
		Audited	Un-Audited	Audited	Audited	Audited
		(1)	(2)	(3)	(4)**	(5)**
1	Income					
	Revenue from operations	18,476.45	17,870.62	25,091.94	83,378.97	37,783.46
	Other Income	534.00	488.75	41.44	1,811.73	60.01
	Total income	19,010.45	18,359.37	25,133.38	85,190.70	37,843.47
2	Expenses					
	a) Cost of materials consumed	6,424.21	5,686.20	6,235.08	24,024.35	12,452.12
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,127.24)	(1,303.88)	1,302.19	(1,105.44)	(2,132.13)
	d) Employee benefits expense	1,952.18	1,756.68	1,627.77	7,372.23	2,963.15
	e) Finance costs	720.37	717.56	174.34	2,181.26	278.92
	f) Depreciation and amortisation expenses	705.34	559.94	595.67	2,386.01	1,149.68
	g) Manufacturing Expenses	2,643.52	2,707.32	2,473.10	10,575.14	5,130.47
	h) Other Expenses	848.10	1,058.35	1,252.60	3,998.12	2,214.55
	Total expenses	12,166.48	11,182.17	13,660.75	49,431.67	22,056.76
3	Profit before exceptional items & Tax (1-2)	6,843.97	7,177.20	11,472.63	35,759.03	15,786.71
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	6,843.97	7,177.20	11,472.63	35,759.03	15,786.71
6	Tax Expenses					
	a) Current tax	1,349.07	1,962.27	2,436.81	8,880.94	3,317.07
	b) Deferred tax	170.83	15.08	1,553.52	(129.93)	1,542.21
7	Net Profit/ (Loss) for the period/year(5-6)	5,324.07	5,199.85	7,482.30	27,008.02	10,927.43
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(18.50)	(82.35)	-	(109.31)	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.65	19.90	-	27.51	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(13.85)	(62.45)	-	(81.80)	-
9	Total Comprehensive Income for the period (7+8)	5,310.22	5,137.40	7,482.30	26,926.22	10,927.43
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	77,010.16	57,756.22
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic	4.18	4.09	5.88	21.22	8.59
	b) Diluted	4.18	4.09	5.88	21.22	8.59
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)



PART - II		CONSOLIDATED				
		For the Quarter Ended			For the year ended	
Sl. No.	PARTICULARS	31/03/2020	31/12/2019	31/03/2019	31/03/2020	31/03/2019
		Audited	Un-Audited	Audited	Audited	Audited
		(1)	(2)	(3)	(4)**	(5)**
1	Income					
	Revenue from operations	18,476.45	17,870.62	25,091.94	83,378.97	37,783.46
	Other Income	534.00	488.75	41.44	1,811.73	60.01
	Total income	19,010.45	18,359.37	25,133.38	85,190.70	37,843.47
2	Expenses					
	a) Cost of materials consumed	6,424.21	5,686.20	6,235.08	24,024.35	12,452.12
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished	(1,127.24)	(1,303.88)	1,302.19	(1,105.44)	(2,132.13)
	d) Employee benefits expense	1,952.18	1,756.68	1,627.77	7,372.23	2,963.15
	e) Finance costs	721.75	760.55	174.34	2,306.60	278.92
	f) Depreciation and amortisation	705.34	559.94	595.67	2,386.01	1,149.68
	g) Manufacturing Expenses	2,643.52	2,707.32	2,473.10	10,575.14	5,130.47
	h) Other Expenses	849.44	1,059.75	1,252.60	4,001.89	2,214.55
	Total expenses	12,169.20	11,226.56	13,660.75	49,560.78	22,056.76
3	Profit before exceptional items, Tax & share in profit/(Loss) of Associates (1-2)	6,841.25	7,132.81	11,472.63	35,629.92	15,786.71
4	Add: Share of profit/(Loss) of Associates.	2,096.88	635.58	-	4,821.26	-
5	Profit before exceptional items, Tax (3+4)	8,938.13	7,768.39	11,472.63	40,451.18	15,786.71
6	Exceptional Items	-	-	-	-	-
7	Profit before Tax (5-6)	8,938.13	7,768.39	11,472.63	40,451.18	15,786.71
8	Tax Expenses					
	a) Current tax	1,349.07	1,962.27	2,436.81	8,880.94	3,317.07
	b) Deferred tax	170.83	15.08	1,553.52	(129.93)	1,542.21
9	Net Profit/ (Loss) for the period/year(7-8)	7,418.23	5,791.04	7,482.30	31,700.17	10,927.43
10	Other Comprehensive Income					
10.a	(i) Items that will not be reclassified to profit or loss	(18.49)	(82.35)	-	(109.30)	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.65	19.90	-	27.51	-
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(13.84)	(62.45)	-	(81.79)	-
11	Total Comprehensive Income for the period (9 + 10)	7,404.39	5,728.59	7,482.30	31,618.38	10,927.43
12	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
13	Other Equity	-	-	-	83,203.45	57,756.22
14	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic	5.83	4.55	5.88	24.91	8.59
	b) Diluted	5.83	4.55	5.88	24.91	8.59
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)



NOTES:-1) The above results were reviewed by the Audit Committee of the Board and approved by the Board of Directors' at their meeting held on 18th June,2020.

2) This is the first financial results of the Company published in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended 31st March,2020 following listing of 127,282,478 fully paid equity shares of Re. 1 each of the Company on BSE Limited (BSE) and National Stock Exchange of India (NSE) in March 2020. The aforesaid shares were allotted at par in terms of the Composite Scheme of Arrangement ('the Scheme') on 27th January, 2020 for an aggregated sum of Rs. 1,272.82 Lakhs, earlier credited to equity share suspense and since then transferred to equity share capital.

3)** Consequent to the demerger of Contract Research and Manufacturing services (CRAMS) Undertaking of the erstwhile Suven Life Sciences Limited as a going concern into the Company, pursuant to the Scheme effective from appointed date being 1st October,2018, the financial results for the year ended 31st March,2020 are not comparable to that extent with the previous corresponding period. Further, for the purpose of calculating earnings per share for the year ended 31st March,2019, the equity shares issued pursuant to the Scheme have been considered effective as on 1st October,2018 and the equity shares of the Company outstanding stand cancelled from the aforesaid date.

4) The Suven Life Sciences Limited (SLSL/Demergered Company) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable the Company (SPL) to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period,SLSL is continuing the CRAMS business in its own name on behalf of SPL. However, for all such operations which were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL.

5) The Company's reportable activity falls under single business segment and hence,the segment disclosure requirements are not applicable.

6)** The figures for the year ended 31st March, 2019 represents figures from 01st October, 2018 (Appointed date of demerger of Demergered Undertaking into the Company) to 31st March, 2019.

7) The figures for the quarters ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto third quarter of the respective financial years. Also, the figures upto the end of the third quarter were only reviewed and not subjected to audit.

8) The Company elected to exercise the option permitted u/s 115BAA of the Income tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised Provision for Income Tax for the year ended 31st March, 2020 and re-measured its Deferred Tax Liability on the basis of the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit & Loss for the year ended 31st March, 2020.

9) The Company has adopted Ind AS 116, "Leases" effective 01st April, 2019, as notified by the Ministry of Corporate Affairs (MCA) in the Companies (Indian Accounting Standards) Amendment Rules, 2019, using modified retrospective method. Accordingly, the Company has not restated comparative information. There is no material impact on transition to Ind AS 116 on retained earnings as at 01st April, 2019 and the financial results for the year ended 31st March, 2020.


10) The COVID-19 impact on the business and going concern assumption of the Company and its subsidiary: On 30th January, 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11th March, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread are expected to continue for more time and may have an adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. To date, the Company has not experienced any major consequences or loss of business which will materially impact the financial conditions of the Company.

11) . There was a fire accident on 26 April 2020 at one of the Company's buildings having research facilities in Jeedimetla, Hyderabad and the insurance claim is under process.


12) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad
Date : 18 th june ' 2020

For SUVEN PHARMACEUTICALS LTD



VENKAT JASTI
Chairman & MD
DIN: 00278028



**SUVEN**
PHARMA**SUVEN PHARMACEUTICALS LTD**

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	31/03/2020	31/03/2019	31/03/2020	31/03/2019
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	35,306.20	26,821.21	35,306.20	26,821.21
(b) Capital Work-in-Progress	10,170.52	11,106.87	10,170.52	11,106.87
(c) 1) Other Intangible Assets	279.59	268.50	279.59	268.50
2) Right of use of assets	88.58	-	88.58	-
(d) Financial Assets				
I. Investments	24,564.73	7.05	30,745.80	7.05
II. Loans	6.00	7.22	6.00	7.22
III. Other Financial Assets	474.59	437.42	474.60	437.42
(e) Deferred tax assets (net)	-	-	-	-
(f) Other non current assets	1,045.08	679.93	1,045.08	679.93
Total Non-Current assets	71,935.29	39,328.20	78,116.37	39,328.20
2 Current assets				
(a) Inventories	17,487.22	15,709.83	17,487.22	15,709.83
(b) Financial Assets				
I. Investments	3,067.33	706.10	3,067.33	706.10
II. Trade Receivables	11,719.58	14,750.17	11,719.58	14,750.17
III. Cash and Cash equivalents	1,157.68	1,090.30	1,169.53	1,090.30
IV. Bank balances other than (III) above	237.97	199.36	237.97	199.36
V. Loans	20.39	10.77	20.39	10.77
VI. Other Financial assets	0.28	0.28	0.28	0.28
(c) Current Tax asset (net)	-	-	-	-
(d) Other current assets	5,462.38	6,506.61	5,462.37	6,506.61
Total Current assets	39,152.83	38,973.42	39,164.67	38,973.42
TOTAL - ASSETS	111,088.12	78,301.62	117,281.04	78,301.62
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	1,272.82	1,272.82	1,272.82	1,272.82
(b) Other Equity	77,010.16	57,756.23	83,203.45	57,756.23
Equity attributable to owners of the company	78,282.98	59,029.05	84,476.27	59,029.05
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liability	51.19	-	51.19	-
II. Borrowings	9,125.25	-	9,125.25	-
(b) Provisions	831.46	594.53	831.46	594.53
(c) Deferred tax Liabilities (net)	2,759.72	2,917.17	2,759.72	2,917.17
(d) Other non current liabilities	-	-	-	-
Total non-current liabilities	12,767.62	3,511.70	12,767.62	3,511.70
Current liabilities				
(a) Financial Liabilities				
I. Lease Liability	40.41	-	40.41	-
II. Borrowings	9,403.80	8,279.36	9,403.80	8,279.36
III. Trade payables				
a) To Micro & Small Enterprises	263.13	73.22	263.13	73.22
b) Other than Micro & Small Enterprises	6,842.44	5,284.27	6,842.44	5,284.27
IV. Other Financial Liabilities	2,319.89	1,420.12	2,319.52	1,420.12
(b) Current Tax liabilities (Net)	525.36	10.96	525.36	10.96
(c) Other Current liabilities	390.84	527.11	390.84	527.11
(d) Provision Employee benefits	251.65	165.83	251.65	165.83
Sub-total - Current liabilities	20,037.52	15,760.87	20,037.15	15,760.87
Total Liabilities	32,805.14	19,272.57	32,804.77	19,272.57
TOTAL - EQUITY AND LIABILITIES	111,088.12	78,301.62	117,281.04	78,301.62

For Suvan pharmaceuticals Ltd

Place : Hyderabad

Date: 18th June, 2020

Venkat Jasti
Chairman & CEO

SUVEN PHARMACEUTICALS LIMITED
Standalone Statement of Cash flows for the year ended 31st March, 2020
(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2020	For the year ended 31st March 2019
A. Cash flow from operating activities		
Profit before tax	35,759.03	15,786.71
Adjustments :		
Depreciation and amortisation expense	2,368.29	1,149.68
Interest Income	(36.06)	(19.76)
Finance Cost	2,181.26	278.92
Gain on sale of Current Investment	623.12	(16.33)
Operating profit before working capital changes	40,895.64	17,179.22
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	3,030.59	(8,489.11)
Inventories	(1,777.39)	(1,708.92)
Other non current financial assets	(35.95)	171.58
Other non current assets	(453.73)	2,703.51
Other current financial assets	(9.62)	4.01
Other current assets	1,044.23	(370.65)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	1,748.08	985.36
Long term provisions	236.93	288.58
Short term provision	(23.49)	(273.18)
Other financial liabilities	899.77	(1,751.42)
Other current liabilities	(136.27)	(392.42)
Cash generated from operating activities	45,418.81	8,346.58
Income taxes paid (net of refunds)	8,640.92	3,306.11
Net Cash flows from operating activities	(A) 36,777.89	5,040.47
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(9,941.46)	(5,659.03)
Proceeds from sale of Property, plant & equipment	13.43	(19.56)
Changes in Investments	(24,557.68)	-
Sale/(purchase) of mutual funds	(2,984.35)	(689.77)
Bank balances not considered as cash and cash equivalents	(38.61)	(199.36)
Interest received	36.06	19.76
Net cash flow from /(used in) investing activities	(B) (37,472.62)	(6,547.96)
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	9,125.25	5,203.03
(Repayment)/Proceeds from short term borrowings	1,124.44	(24.64)
Finance Cost	(1,906.88)	(278.92)
Changes In Lease Liability	91.59	-
Dividends paid to equity holders (including dividend distribution tax)	(7,672.29)	(2,301.69)
Net cash flow from /(used In) financing activities	(C) 762.11	2,597.78
Net increase/(decrease) in cash and cash equivalents	(A+B+C) 67.38	1,090.29
Cash and cash equivalents as at the beginning of the year	1,090.30	-
Cash and cash equivalents at the end of the year	1,157.68	1,090.29
Cash and cash equivalents	1,157.68	1,090.29
Balances per statement of cash flows	1,157.68	1,090.29

For Suven Pharmaceuticals Limited



Venkat Jasti
 Chairman & Managing Director
 DIN: 00278028



Place : Hyderabad
 Date : 18.06.2020

SUVEN PHARMACEUTICALS LIMITED

Consolidated Statement of Cash flows for the year ended 31st March, 2020

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2020	For the year ended 31st March 2019
A. Cash flow from operating activities		
Profit before tax	40,451.18	15,786.71
Adjustments :		
Depreciation and amortisation expense	2,368.29	1,149.68
Interest Income	(36.06)	(19.76)
Finance Cost	2,306.60	278.92
Gain on sale of Current Investment	623.12	(16.33)
Operating profit before working capital changes	45,713.13	17,179.22
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	3,030.59	(8,489.11)
Inventories	(1,777.39)	(1,708.92)
Other non current financial assets	(35.95)	171.58
Other non current assets	(453.73)	2,703.51
Other current financial assets	(9.62)	4.01
Other current assets	1,044.23	(370.65)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	1,748.08	985.36
Long term provisions	236.93	288.58
Short term provision	(23.49)	(273.18)
Other financial liabilities	899.40	(1,751.42)
Other current liabilities	(136.27)	(392.42)
Cash generated from operating activities	50,235.93	8,346.58
Income taxes paid (net of refunds)	8,640.92	3,306.11
Net Cash flows from operating activities	(A) 41,595.01	5,040.47
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(9,941.46)	(5,659.03)
Proceeds from sale of Property, plant & equipment	13.43	(19.56)
Changes in Investments	(30,738.76)	-
Sale/(purchase) of mutual funds	(2,984.35)	(689.77)
Foreign currency translation reserve	1,501.14	-
Bank balances not considered as cash and cash equivalents	(38.61)	(199.36)
Interest received	36.06	19.76
Net cash flow from /(used in) investing activities	(B) (42,152.55)	(6,547.96)
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	9,125.25	5,203.03
(Repayment)/Proceeds from short term borrowings	1,124.44	(24.64)
Finance Cost	(2,032.22)	(278.92)
Changes In Lease Liability	91.59	-
Dividends paid to equity holders (including dividend distribution tax)	(7,672.29)	(2,301.69)
Net cash flow from /(used In) financing activities	(C) 636.77	2,597.78
Net increase/(decrease) in cash and cash equivalents	(A+B+C) 79.23	1,090.29
Cash and cash equivalents as at the beginning of the year	1,090.30	-
Cash and cash equivalents at the end of the year	1,169.53	1,090.29
Cash and cash equivalents	1,169.53	1,090.29
Balances per statement of cash flows	1,169.53	1,090.29

For Suven Pharmaceuticals Limited



Venkat Jasti

Venkat Jasti
Chairman & Managing Director
DIN: 00278028

Place : Hyderabad
Date : 18.06.2020



**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS
AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF SUVEN PHARMACEUTICALS LIMITED

Opinion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2020 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2020 (refer 'Other Matters' section below) which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2020 ("the Statement") of SUVEN PHARMACEUTICALS LIMITED ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2020:


- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2020

With respect to the Standalone Financial Results for the quarter ended March 31, 2020, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2020, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2020

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2020 under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that



18/06/2020

the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2020 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2020 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and Fairview and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for

(a) Audit of the Standalone Financial Results for the year ended March 31, 2020

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2020 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



18/06/2020

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained upto the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



18/06/2020


(b) Review of the Standalone Financial Results for the quarter ended March 31, 2020

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2020 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- On account of the COVID-19 related lock-down restrictions, we were not able to physically observe the verification of inventory that was carried out by the Management. Consequently, we have performed alternate procedures to audit the existence of Inventory as per the guidance provided in SA 501 "Audit Evidence – Specific Considerations for Selected Items" and have obtained sufficient audit evidence to issue our unmodified opinion on these Standalone Financial Results. Our report on the Statement is not modified in respect of this matter.
- Attention is drawn to Note 7 to the Statement which states that the Standalone Financial Results includes the results for the Quarter ended March 31, 2020 being the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the current financial year Our report is not modified in respect of this matter.
- Attention is drawn to Note 7 to the Statement, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2018. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2019. Our report is not modified in respect of this matter.

For **KARVY & CO,**
Chartered Accountants
(Firm Registration No. 001757S)


AJAY KUMAR KOSARAJU
Partner
Membership No. 021989
UDIN: 20021989AAAABX8664



Place: Hyderabad
Date: June 18 2020



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUVEN PHARMACEUTICALS LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2020 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2020 (refer "Other Matters" section below), which were subject to limited review by us, both included in the accompanying "Consolidated Financial Results for the quarter and year ended March 31, 2020" of **SUVEN PHARMACEUTICALS LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") and its share of the net profit after tax and total comprehensive income of its associate company for the quarter and year ended March 31, 2020, (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial information of the subsidiary and associate referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2020:

(i) includes the results of the following entities:


Name of the Company	Country	Relationship
SUVEN PHARMA INC	USA	Wholly Owned Subsidiary
RISING PHARMA INC	USA	Associate

(ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group and its associate for the year ended March 31, 2020.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2020

With respect to the Consolidated Financial Results for the quarter ended March 31, 2020, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit reports for the year ended March 31, 2020 of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated



18/06/2020

Financial Results for the quarter ended March 31, 2020, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2020

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2020 under the provisions of the Act and the Rules there under and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2020, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2020 that give a true and fair view of the consolidated net profit/loss and consolidated other comprehensive income and other financial information of the Group including its associate in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group, its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters



18/06/2020

related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and its associate are responsible for overseeing the financial reporting process of the Group and associate.

Auditor's Responsibilities for

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2020

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2020 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.



18/06/2020

- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Information of the entities within the Group and its associate to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of entities included in the Annual Consolidated Financial Results of which we are the independent auditors .For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2020

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2020 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.



18/06/2020


As part of annual audit we also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- Attention is drawn to Note 7 to the Statement which states that the Consolidated Financial Results includes the results for the Quarter ended March 31, 2020 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year .Our report is not modified in respect of this matter.
- Attention is drawn to Note 7 to the Statement, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2018. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2019. Our report is not modified in respect of this matter.
- We did not audit the financial information of the subsidiary included in the consolidated financial results, whose financial information reflect total assets of Rs.25,929.35 lakhs as at March 31, 2020 and total revenues of Rs.NIL for the year ended March 31, 2020, total net loss of Rs.(129.10) lakhs for year ended March 31, 2020 and total comprehensive income of Rs. (129.10) lakhs for the year ended March 31, 2020.The consolidated financial results also includes the Group's share of profit after tax of Rs.4,821.26 lakhs for the year ended March 31, 2020, as considered in the Statement, in respect of the associate whose financial information has not been audited by us. These financial information have been audited, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and associate is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For **KARVY & CO,**
Chartered Accountants
(Firm Registration No. 001757S)


AJAY KUMAR KOSARAJU
Partner
Membership No. 021989
UDIN: 20021989AAAABY2831



Place: Hyderabad
Date: June 18, 2020

18/06/2020

NEWS RELEASE

HYDERABAD, INDIA (18 June' 2020) -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced audited financial results for the quarter and year ended 31 Mar 2020. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 18 June' 2020 at Hyderabad.

CONDENCED STATEMENT OF OPERATIONS				All figures in INR Lakhs, except EPS			
	Stand Alone - 3 Months ended			FY-Stand Alone (1)		FY-Consolidated (2)	
	Q4 Mar 20	Q3 Dec 19	Q4 Mar 19	FY Mar 20	FY Mar 19	FY Mar 20	FY Mar 19
Revenue	19,010.46	18,359.37	25,133.38	85,190.70	37,843.47	85,190.70	37,843.47
Operational expenses	10,740.78	9,904.67	12,890.74	44,864.41	20,628.16	40,326.31	20,628.16
Depreciation and Amortisation	705.34	559.94	595.67	2,386.01	1,149.68	2,386.01	1,149.68
Finance cost	720.37	717.56	174.34	2,181.26	278.92	2,027.21	278.92
Total expenses	12,166.49	11,182.17	13,660.75	49,431.68	22,056.76	44,739.53	22,056.76
Tax	1,519.90	1,977.35	3,990.33	8,751.00	4,859.28	8,751.00	4,859.28
Profit After Tax for the period/year	5,324.07	5,199.85	7,482.30	27,008.02	10,927.43	31,700.17	10,927.43
Other comprehensive income	(13.85)	(62.45)	-	(81.80)	-	(81.80)	-
Total comprehensive income	5,310.22	5,137.40	7,482.30	26,926.22	10,927.43	31,618.37	10,927.43
Paid up equity capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
Earnings per share of Rs.1 each (EPS)	4.18	4.09	5.88	21.22	8.59	24.91	8.59

(1) Post demerger, as approved by Honorable National Company Law Tribunal (NCLT) on 6 Jan 2020, your Company has become Resultant entity with the appointed date effective 1 Oct 2018 and hence the annual figures of previous year are not comparable

(2) On consolidation of the accounts of Suven Pharma, Inc., USA, wholly owned subsidiary, the PAT includes INR 4,821 lakhs of unrealised share of profit in Rising Pharma Holdings, Inc., USA, an associate company.

- The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
- During the year, Suven Life Sciences Limited, (Group company), a 30 years old entity, demerged CRAMS business undertaking, now integrated to your Company and the Group Company retained discovery research and clinical development of new molecules focused on Central Nervous System (CNS) disorders.
- During the year your Company invested through Suven Pharma, Inc., for a minority stake in Rising Pharma Holdings, Inc., a generic formulations development and distribution entity, operating out of New Jersey, USA.
- There was a fire accident on 26 April 2020 at one of the Company's buildings having research facilities in Jeedimetla, Hyderabad and the insurance claim under process.
- On 30 Jan 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11 Mar 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. To date, the Company has not experienced any major consequences or loss of business which will materially impact the financial conditions of the Company.

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited

CS/NSE/BSE/2020-21
June 18, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Declaration in respect of Audit Reports with unmodified opinion for the financial year ended 31st March 2020

.....

We hereby declare that the Statutory Auditors of the Company, M/s. Karvy & Co., Chartered Accountants have issued an Audit Reports with unmodified opinion on audited financial results (Standalone and Consolidated) for the quarter and year ended 31st March, 2020.

We request you to take this document on your record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



Venkateswarlu Jasti
Chairman & Managing Director

Suven Pharmaceuticals Limited

CS/NSE/BSE/2020-21
June 18, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Details of Key Managerial Personnel (“KMP”) for determining materiality under Regulation 30(5) of SEBI (Listing and Obligation Disclosure Requirements) Regulations, 2015

.....

Pursuant to Regulation 30(5) of SEBI (Listing and Obligation Disclosure Requirements) Regulations, 2015, please find below the details of the Key Managerial Personnel who have been jointly severally authorized by the Board of Directors of the Company.

To determine the materiality of an event or information under this regulation and also making disclosures to stock exchange(s):

Name	Designation	E-mail ID
Shri Venkateswarlu Jasti	Chairman & Managing Director	jasti@suvenpharm.com
Mr. Venkatraman Sunder	Vice President (Corporate Affairs)	vsunder@suvenpharm.com
Mr. K Hanumantha Rao	Company Secretary	khrao@suvenpharm.com
Mr. P Subba Rao	Chief Financial Officer	psrao@suvenpharm.com
Contact Address:	Suven Pharmaceuticals Limited SDE Serene Chambers, 3rd Floor, Road No. 5, Banjara Hills, Hyderabad – 500034, Telangana	
Contact No.	040-2354 9414	

This is for your information and records.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K. Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited

CS/NSE/BSE/2020-21
June 18, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Disclosures on impact analysis of COVID-19 pandemic on company's operations under Regulation 33 of SEBI LODR Regulations, 2015

.....

Pursuant to Regulation 33 of SEBI (Listing and Obligation Disclosure Requirements) Regulations, 2015, please find below the details of the impact analysis of COVID-19 pandemic on company's operations.

Impact of the COVID-19 pandemic on the business:

1	Operations including the factories/ units/ office spaces functioning during lockdown	Suven Pharmaceuticals Ltd (the Company) and our facilities were never closed during lockdown and being part of essential services, our Company was allowed to operate. There were few disruptions due to labour movement and their non-availability. However, the company was able to address the issues and there was no major impact in our operations.
2	Schedule, if any, for restarting the operations	Not applicable as we have not closed our operations.
3	Steps taken to ensure smooth functioning of operations	The Company issued COVID-19 alert as per WHO guidelines and adopted suitable policies to safe guard our employees and for smooth functioning of our operations. The Company has taken adequate safety measures, including social distancing, wearing masks within our premises and multiple levels of sanitizations.
4	Estimation of the future impact of COVID-19 on its operations	So far there was no serious impact of COVID-19 on our operations. It will be difficult to quantify future impact at this point of time.

Suven Pharmaceuticals Limited

Details of impact of CoVID-19 on our Company:

1	Capital and financial resources	Not affected.
2	Profitability and Liquidity	To date, the Company has not experienced any major consequences or loss of business which will materially impact the financial conditions of the Company. However, due to increased cost on logistics and others costs associated with implementation of COVID-19 related Standard Operating Procedures (SOPs), there may be some impact on the Company's profitability in future, the quantification of the same will be difficult at this point of time.
3	Ability to service debt and other financing arrangements	The Company is able to service its debts and financial arrangements.
4	Assets	No impact.
5	Internal financial reporting and control	Not affected.
6	Supply chain	There was a temporary disruption in relation to logistics during the lockdown period and the same eased without any major impact on our operations or services.
7	Demand for its products/services	Given the multiple geographies in which the Company operate, any impact of lockdown or disruptions in different geographies may have impact on our products and services in future. However, there was no impact on demand for product and service offerings as of now.
8	Existing contracts/agreements where non-fulfilment of the obligations by any party will have significant impact on the Company's business	Except for few dealys during lockdown, mostly related to logistics, there was no major effect in delivery of our products and services, which may impact significantly.

This is for your information and records.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited